hotspot -WSS

hotspot

author：entertainment 2025-10-02 22:58:50 - browse：9524

Zepbound, a injectable drug on a gradient background of dark purple and green — biotech coverage from STAT — Illustration: STAT; Source: Eli Lilly/AP

A California biotech developing a combination therapy with the obesity drug Zepbound has raised a $170 million Series D round.

The company, BioAge, raised money from more than a dozen investors. Sofinnova Investments led the round, which also included Eli Lilly and Amgen’s venture arms and previous investor Andreessen Horowitz.

BioAge’s primary focus is in developing medications that boost a person’s healthspan, or the number of healthy years a person lives. The company has drugs in development for neuroinflammation and brain aging. But the majority of the Series D proceeds will be used to develop the company’s lead drug candidate azelaprag, which is being tested in combination with Zepbound. That drug program is what grabbed Sofinnova’s attention, according to managing partner Jim Healy, who recently became chairman of BioAge’s board.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Trump demands the U.S. pay no more for drugs than other countries … again
Next article： 7 more heat

focus

WSS

Roche drug slashes death risk in early

'Stay indoors': Escaped wild animal on the loose in Berlin prompts urgent citywide search

STAT Readout: Friday, Oct. 20 biotech updates

ADCs take center stage as promising cancer treatments

STAT Summit: The economic case for universal basic health care

Roche drug slashes death risk in early

hotspot

hotspot

focus

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Cassava Sciences’ Alzheimer’s clinical trials should be halted

Heart attack and stroke risk calculators need revising

ADCs take center stage as promising cancer treatments

Cancer drug shortages should be causing more outrage

Stanford president's case begs question: Who takes blame?

George Santos makes 1st court appearance after pleading not guilty to 13 counts

FDA clears Verve to begin U.S. study of gene

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Mass General totes up its waste in a move to tackle climate change

focus

The problems with dementia villages

Cassava Sciences’ Alzheimer’s clinical trials should be halted

Questions loom on AstraZeneca cancer drug as safety concerns ebb

A Q&A with Gavi’s Seth Berkley on vaccines, Covid, and more

Mass General totes up its waste in a move to tackle climate change

Awakening the world to the whoosh: A patient's crusade

focus

knowledge

hotspot

focus